blank
logo-
Call: +66 64 505 5599

MENU

Call: +66 64 505 5599
logo-
Call: +66 64 505 5599
why-doctors-dont-mention-stem-cell-therapy

Your Doctor Hasn’t Mentioned Stem Cells. Here’s Why

If you have spent any time reading about regenerative medicine, you have probably asked yourself some version of this question. The research exists. Clinical trials are running. Patients are reporting results. So why does your orthopedic surgeon keep steering you toward cortisone injections and physical therapy, and never once raise the subject of stem cells?

The answer is not that stem cell therapy is fringe science. It is that the path from promising research to standard clinical practice is long, slow, and expensive — and most doctors are trained to work within that system, not around it.

How Treatments Become Standard of Care

Before any therapy becomes something a doctor routinely recommends, it has to clear a series of regulatory and institutional hurdles. It needs large-scale randomised controlled trials demonstrating safety and efficacy across diverse patient populations. It needs regulatory approval in the relevant jurisdiction. It needs to be adopted into clinical guidelines by professional bodies. And it needs to be covered — or at least considered — by insurance systems that ultimately influence what gets offered to patients.

This process takes years, sometimes decades, and it costs enormous amounts of money. Pharmaceutical companies fund it for drugs because they can patent the molecule and recover the investment. Cell therapies are harder to patent in the same way, which makes the commercial incentive to fund large-scale trials more complicated. The science can be genuinely promising while the regulatory pathway remains unresolved.

Where the Evidence Actually Stands

This is worth being clear about. MSC therapy is not without evidence — it is without the specific type of standardised, large-scale evidence that regulatory bodies require before approving a treatment for widespread use. Those are different things.

Hundreds of clinical trials using mesenchymal stem cells are currently registered and active globally, covering conditions from knee osteoarthritis and spinal cord injury to neurological disorders and autoimmune disease. Results across many of these trials have been encouraging on safety and on clinical outcomes. The challenge the field is working through is consistency — standardising cell sources, doses, administration routes, and patient selection criteria so that results are reproducible enough to satisfy regulatory requirements.

That gap between “promising clinical evidence” and “approved standard treatment” is precisely where stem cell therapy sits right now for most orthopedic and neurological conditions. It is not a gap that reflects a lack of scientific credibility. It reflects the realities of how medicine moves from research to routine practice.

Why Your Doctor Doesn’t Bring It Up

Most physicians are trained to recommend treatments that sit within established guidelines. Recommending something outside those guidelines carries professional and medico-legal risk, even when the individual doctor may be personally aware of the evidence. In many healthcare systems, doctors also operate under time constraints and institutional protocols that make exploring emerging therapies difficult during a standard consultation.

There is also the matter of familiarity. Stem cell therapy is not part of the training curriculum for most orthopedic surgeons or neurologists who qualified more than a decade ago. They are not being dismissive — they are working with the knowledge and risk framework their profession has given them.

This does not mean the therapy is unavailable or inappropriate. It means finding it requires going outside the standard referral pathway, which most patients only do when conventional options have stopped producing results.

What Selectivity Actually Looks Like

One legitimate concern in the stem cell space is that not all clinics offering these therapies operate to the same standard. Some make claims that go well beyond what the evidence supports. This is a real problem, and it is one reason regulators and mainstream physicians remain cautious — the bad actors in any emerging field damage trust in the whole area.

Your doctor hasn’t mentioned stem cells because the system they operate in has not yet caught up with the research. That is a structural reality, not a verdict on the therapy itself. If you are dealing with a condition that conventional treatment has not resolved, understanding what regenerative medicine can and cannot offer is a reasonable next step — as long as you are getting that information from a physician-led clinic that applies the same critical standards to stem cell therapy that it does to everything else.

About EDNA Wellness

EDNA Wellness is a surgeon-led regenerative medicine center in Bangkok, specializing in orthopedic and neurological conditions using Umbilical Cord–Derived Mesenchymal Stem Cells (UC-MSCs).

All cases are reviewed by orthopedic surgeons and neurosurgeons, with a focus on clinical indication, patient safety, and realistic treatment expectations. Stem cell therapy is recommended selectively, and alternative treatments are considered when more appropriate.

For more information or to book a consultation:

LINE: @ednawellness

WhatsApp: +66 (0) 64 505 5599

www.ednawellness.com

References

Related Posts

error:Content is protected !!
blank